Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.

Viktoria BergqvistMohammad KadivarDaniel MolinLeif AngelisonPer HammarlundMarie OlinJörgen TorpOlof GripStefan NilsonErik HertervigJan LillienauJan Marsal

Published in: Therapeutic advances in gastroenterology (2018)

This is the largest study of switched IBD patients published to date, and it demonstrates that switching from Remicade to CT-P13 may be done with preserved therapeutic effectiveness and safety in both CD and UC.

Keyphrases

patients with inflammatory bowel disease
end stage renal disease
computed tomography
image quality
dual energy
ejection fraction
newly diagnosed
contrast enhanced
chronic kidney disease
magnetic resonance imaging